Hill-Rom Holdings, Inc. (NYSE:HRC) – Analysts at Northcoast Research dropped their Q1 2020 EPS estimates for Hill-Rom in a research report issued on Tuesday, November 5th. Northcoast Research analyst D. Keiser now expects that the medical technology company will post earnings of $1.08 per share for the quarter, down from their previous forecast of $1.09. Northcoast Research also issued estimates for Hill-Rom’s Q2 2020 earnings at $1.19 EPS, Q3 2020 earnings at $1.34 EPS and FY2020 earnings at $5.54 EPS.

Other research analysts also recently issued research reports about the stock. Barclays upped their price target on shares of Hill-Rom from $108.00 to $116.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 6th. ValuEngine downgraded shares of Hill-Rom from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Morgan Stanley upped their price target on shares of Hill-Rom from $108.00 to $113.00 and gave the stock an “equal weight” rating in a research report on Monday, November 4th. KeyCorp upped their price target on shares of Hill-Rom from $114.00 to $125.00 and gave the stock an “overweight” rating in a research report on Monday, August 5th. Finally, UBS Group upped their price target on shares of Hill-Rom from $122.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, November 4th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $118.67.

HRC opened at $103.97 on Friday. Hill-Rom has a twelve month low of $81.85 and a twelve month high of $111.63. The company has a quick ratio of 1.10, a current ratio of 1.31 and a debt-to-equity ratio of 1.13. The company has a 50-day moving average price of $102.71 and a 200 day moving average price of $103.06. The company has a market cap of $6.90 billion, a PE ratio of 20.47, a price-to-earnings-growth ratio of 1.88 and a beta of 0.83.

Hill-Rom (NYSE:HRC) last released its quarterly earnings results on Friday, November 1st. The medical technology company reported $1.69 earnings per share for the quarter, topping the consensus estimate of $1.65 by $0.04. Hill-Rom had a net margin of 5.24% and a return on equity of 21.67%. The firm had revenue of $782.80 million during the quarter, compared to the consensus estimate of $759.14 million. During the same quarter in the prior year, the firm earned $1.63 EPS. The company’s revenue for the quarter was up 3.1% on a year-over-year basis.

In other Hill-Rom news, SVP Paul Sherwood Johnson sold 6,470 shares of the stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $104.26, for a total value of $674,562.20. Following the completion of the sale, the senior vice president now owns 8,215 shares in the company, valued at approximately $856,495.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.73% of the stock is currently owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the business. Nuveen Asset Management LLC grew its stake in shares of Hill-Rom by 6,123.6% in the 2nd quarter. Nuveen Asset Management LLC now owns 607,796 shares of the medical technology company’s stock valued at $63,587,000 after buying an additional 598,030 shares during the period. BlackRock Inc. boosted its position in shares of Hill-Rom by 4.9% during the 2nd quarter. BlackRock Inc. now owns 6,649,313 shares of the medical technology company’s stock worth $695,650,000 after purchasing an additional 307,825 shares during the period. Dana Investment Advisors Inc. purchased a new position in shares of Hill-Rom during the 2nd quarter worth approximately $21,336,000. AQR Capital Management LLC boosted its position in shares of Hill-Rom by 97.0% during the 2nd quarter. AQR Capital Management LLC now owns 368,857 shares of the medical technology company’s stock worth $38,590,000 after purchasing an additional 181,663 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Hill-Rom by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 6,322,476 shares of the medical technology company’s stock worth $661,458,000 after purchasing an additional 163,177 shares during the period. Institutional investors own 82.61% of the company’s stock.

About Hill-Rom

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

See Also: Golden Cross

Earnings History and Estimates for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.